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Sample size calculation in
cost-effectiveness cluster randomized
trials: optimal and maximin approaches
Md. Abu Manju,*† Math J. J. M. Candel and Martijn P. F. Berger
In this paper, the optimal sample sizes at the cluster and person levels for each of two treatment arms are
obtained for cluster randomized trials where the cost-effectiveness of treatments on a continuous scale is stud-
ied. The optimal sample sizes maximize the efficiency or power for a given budget or minimize the budget for
a given efficiency or power. Optimal sample sizes require information on the intra-cluster correlations (ICCs)
for effects and costs, the correlations between costs and effects at individual and cluster levels, the ratio of the
variance of effects translated into costs to the variance of the costs (the variance ratio), sampling and measuring
costs, and the budget. When planning, a study information on the model parameters usually is not available.
To overcome this local optimality problem, the current paper also presents maximin sample sizes. The maximin
sample sizes turn out to be rather robust against misspecifying the correlation between costs and effects at the
cluster and individual levels but may lose much efficiency when misspecifying the variance ratio. The robustness
of the maximin sample sizes against misspecifying the ICCs depends on the variance ratio. The maximin sample
sizes are robust under misspecification of the ICC for costs for realistic values of the variance ratio greater than
one but not robust under misspecification of the ICC for effects. Finally, we show how to calculate optimal or
maximin sample sizes that yield sufficient power for a test on the cost-effectiveness of an intervention. Copyright
© 2014 John Wiley & Sons, Ltd.
Keywords: cluster randomized trials; cost-effectiveness analysis; maximin design; optimal design; sample
size calculation
1. Introduction
Decision makers have need of cost-effectiveness analyses (CEAs) to evaluate new healthcare technolo-
gies or interventions. These interventions are often evaluated with well-designed randomized controlled
trials, where one randomly assigns individuals such as patients to treatments [1]. Randomized controlled
trials with randomization carried out at the cluster level, that is, all the persons within the same clus-
ter such as a hospital or general practitioner receive the same treatment, are called cluster randomized
trials (CRTs). For example, a CRT in CEAs evaluated alternative interventions for preventing postnatal
depression where general practices were randomly assigned to the interventions [2]. This study aimed
at estimating incremental costs (UK pounds (£)) and effectiveness in terms of quality-adjusted life-years
(QALYs) of interventions to prevent depression for postnatal women. In multicentre trials, on the other
hand, individuals within clusters, as opposed to whole clusters, are randomly assigned to the treatments.
Multicentre trials are more efficient [3] but, because of treatment contamination or logistic reasons,
not always possible in practice. In these cases, CRTs are a suitable or, in many cases, even the only
alternative.
A fundamental issue in CRTs is that the individual costs and effects data may vary noticeably between
clusters. So CRTs on cost-effectiveness of interventions may result in a hierarchical or multilevel struc-
ture, that is, the responses of the individuals treated in the same centre or cluster are correlated. Failure
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to acknowledge this between-cluster variability in CEAs may give misleading conclusions in an eco-
nomic evaluation. The linear mixed model is a suitable framework to analyze the cost-effectiveness data
gathered in CRTs [4].
An important part of the design of CRTs is the calculation of sample size (number of clusters and
persons in each cluster), which gives high statistical power to show the cost-effectiveness of a treatment.
The optimal sample size maximizes the efficiency of the treatment effect estimator and thus maxi-
mizes power of the Wald test on the treatment effect, given the constraints on sample sizes and costs
for selecting samples. Formulas for computing optimal sample sizes for CRTs under a given budget or
power are available in the literature, but these optimal designs are only based on the effectiveness of an
intervention [3, 5, 6].
Nowadays researchers are not only interested in effectiveness but also try to include costs and effec-
tiveness simultaneously in trials. In the literature on economic evaluation, there are sample size formulas
that account for costs and effects at the same time [7–9]. The required sample sizes depend on the
variance and correlation of costs and effects. However, the formulas for sample size calculation given
by [7–9] are developed for single-level studies and thus ignore between-cluster variability, which is an
important characteristic of cost-effectiveness CRTs. Ignoring the between-cluster variability in sample
size calculation will lead to too small sample sizes, and thus to underpowered studies [3].
For the design of cost-effectiveness CRTs, the question is how many clusters and how many persons
in each cluster are needed to prove the cost-effectiveness of an intervention. This paper proposes an
optimal design for cost-effectiveness CRTs. Such an optimal design will be derived taking net monetary
benefit [10] as an outcome variable, which accounts for both effectiveness and costs of two treatments.
The optimal design literature for CRTs on efficacy shows that optimal designs depend on the model
parameters and requires knowledge of these parameters that may be unknown at the beginning of
the study. This is called the local optimality problem [11, 12]. Although parameters are unknown,
some information may be available from similar previous studies, yielding plausible ranges for those
parameters.
Three approaches are available to deal with the local optimality problem, namely the sequential design
approach, the Bayesian approach, and the maximin approach. The sequential approach updates the
design based on updated parameter estimates and often requires a relatively long time to complete [13].
The Bayesian approach evaluates the expected efficiency of the design over the prior distributions of the
model parameters and yields a design that performs well on average [14]. For the Bayesian approach,
knowledge of the prior distributions of relevant parameters is needed. Finally, the maximin approach
maximizes the minimum efficiency of the treatment effect estimator [11]. The maximin design thus has
the best possible worst-case performance, in this sense differing from the Bayesian and the sequential
approaches. From a practical point of view, this strategy is attractive in that the researcher only needs to
specify plausible ranges for the unknown parameters. To accommodate the local optimality problem, the
current paper proposes a maximin design for cost-effectiveness CRTs.
The paper is structured as follows. First, we present the model for analyzing individual level data
on net monetary benefit that are gathered in CRTs. Second, we derive optimal sample sizes under a
budget constraint for cost-effectiveness CRTs, minimizing the variance of the estimator of the average
incremental net monetary benefit for comparing two interventions. Third, to accommodate uncertainty
with respect to parameter values, maximin sample size formulas will be derived. We show through a
numerical evaluation how robust these maximin sample sizes are against misspecification of parameter
boundaries. Next, a formula is given to calculate the required sample sizes for a given power of the test
on the cost-effectiveness of a treatment. We then apply our strategies for sample size calculation to a
case study and discuss the findings. The final section summarizes the results, points out limitations of
the present method, and gives suggestions for further research.
2. Model specification
In CRTs, the group or cluster is randomized to a treatment, not the individual. The key implication of
CRTs for economic data is that cost-effectiveness of a particular treatment may vary markedly among
the clusters (e.g., [10]). In addition, there may be a correlation in costs and effects not only among the
individuals within the same cluster but also between clusters. In what follows, we will present a method
for CEAs, accommodating both features of such data. In the treatment and control conditions, we have
kt and kc clusters, respectively. In cluster j.j D 1; 2; : : : ; kt / of the treatment condition, there are mj
Copyright © 2014 John Wiley & Sons, Ltd. Statist. Med. 2014, 33 2538–2553
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persons, and in cluster j .j D kt C 1; kt C 2; : : : ; kt C kc/ of the control condition, there are nj per-
sons. Thus, the number of persons in the treatment group is
ktP
jD1




nj . Let Cij and Eij be the costs and effects of person i in cluster j , where
i D 1; 2; : : : ; mj for a person in the treatment arm, and i D 1; 2; : : : ; nj for a person in the control arm.
A suitable technique to estimate incremental costs and effects of the treatment versus the control
condition, allowing for clustering, is the following bivariate linear mixed model [4]:

































The intervention is represented by a variable tj , which takes the value 0 if the j th cluster is in the
control condition and 1 if the j th cluster is in the treatment condition. Incremental effects and costs are
represented by slope coefficients ˛1 and 1. The random components u0j and v0j indicate the grand
mean deviance of effects and costs for the j th cluster, respectively, and are assumed to be bivariate
normal with zero mean and variances 2u and 
2
v . The u0j ’s for different j .j D 1; 2; : : : ; kt C kc/ are
independent from each other as well as the v0j ’s for different j .j D 1; 2; : : : ; kt C kc/, and u0j is
independent from v0k for j ¤ k. The models in Equation (1) take care of the hierarchical or nested
structure by including random components for clusters. These models are known as multilevel or hier-
archical models. Here we have a two-level model, with, for instance, patients being nested within
hospitals. The correlation uv .16 uv 6 1/ represents the cost–effect correlation between random
effects u0j and v0j at the cluster level. The error terms ıij and "ij also have a bivariate normal distri-
bution with zero mean and variances 2
ı
and 2" , respectively. The terms ıij for all i

i D 1; 2; : : : ; mj
or i D 1; 2; : : : ; nj

and j.j D 1; 2; : : : ; kt C kc/ are independent from each other. This also holds for
the terms "ij for all i

i D 1; 2; : : : ; mj or i D 1; 2; : : : ; nj

and j .j D 1; 2; : : : ; kt C kc/. The cost–
effect correlation between random effects "ij and ıij at the individual level is ı" .16 ı" 6 1/. The
other model assumptions are that "ij and ıi 0j 0 are independent for i ¤ i 0 or j ¤ j 0; u0j is inde-
pendent from "ij and ıij , and v0j is independent from "ij and ıij . The outcomes of individuals within
the same cluster have a positive correlation, measured by the intra-cluster correlation (ICC) for effects
0 6 e D 2u = .2u C 2ı / 6 1 and costs 0 6 c D 2v = .2v C 2" / 6 1. Actually, the ICC describes the
proportion of total variation due to clustering. In what follows, the variances of Cij and Eij are denoted
as V.Eij /D 2u C 
2
ı
and V.Cij /D 2v C 
2
" .
In Equation (1), the costs and effects are expressed on their original scales, but the net-benefit frame-
work gives us the opportunity to express both costs and effects on the same scale, either as net monetary
benefit (NMB) or as net health benefit by using an additional term  denoted as the ceiling ratio [15]. The
ceiling ratio .0 6  < 1/ translates efficacy into monetary units and is interpreted as the maximum
value (on a monetary scale) associated with an extra unit of effect (e.g., health gain) [15]. Let NMBij
represent the net monetary benefit for the i th individual in the j th cluster. This is defined as




is the net health benefit for the i th individual in the j th cluster. As net health
benefit can easily be translated into net monetary benefit and vice versa, we will only consider net








0C 1tj C v0j C "ij

; or D ˇ0C ˇ1tj Cw0j C!ij : (3)
Here, the intercept ˇ0.D ˛0  0/ is the average NMB in the control condition. Similarly, the average
NMB for the treatment condition is ˇ0Cˇ1. So ˇ1.D ˛11/ stands for the average incremental NMB
(INMB), and an intervention is cost-effective and thus should replace the control treatment, if the average
INMB> 0. For example, if a decision maker is willing to pay £30,000 for a year of life, the intervention
2540
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will be cost-effective if average INMB > 0 for  D £30; 000. For  D 0 (or  ! 1/, Equation (3)
reduces to the second part of Equation (1), that is, the regression model of costs on treatment (or the first
part of Equation (1), that is, the regression model of effects on treatment). It follows from Equation (1)
that the random components w0j .D u0j  v0j / and !ij

D ıij  "ij

are normally distributed with
means of zeros and variances V.w0j / and V.!ij /, respectively, where V.w0j /D 22uC
2
v2uvuv
and V.!ij /D 22ı C 
2
"  2ı"ı". The w0j ’s are independent for all j , and !ij ’s are independent
for all i and j . The components w0j and !ij are independent of each other.
3. Optimal sample sizes
In order to derive optimal sample sizes, we assume that the cluster sizes in the treatment and con-
trol conditions are all m and n, respectively, that is, mj D m for j D 1; 2; : : : ; kt and nj D n for
j D ktC1; ktC2; : : : ; ktCkc . There are several methods to estimate the parameters of the linear mixed
effects model in Equation (3), and maximum likelihood (ML) is the most common one. Verbeke and
Molenberghs [16] gave a general formula for the ML estimator of fixed effects. From this expression,





































































where A D 'e C c  2uv
p
ec' and B D '.1  e/C .1  c/  2ı"
p
.1 e/.1 c/'. The
parameter ' D V.Eij / = V .Cij / is the ratio of the total variance for effects translated into costs .Eij /
to the total variance for costs .Cij / .0 6 ' < 1/. Equation (5) shows that the asymptotic variance
of Ǒ1 depends on the number of clusters, the cluster sizes in both arms and the ICC for effects, e , and
costs, c , the correlation at cluster level, uv , and individual level, ı", and the variance ratio '.
To derive the optimal sample sizes, the variance of the treatment effect estimator Ǒ1 is minimized
under certain constraints with respect to sample sizes and costs for selecting samples. For the Wald test
of Ǒ1 in Equation (4), this implies that the optimal design yields maximum power at lowest costs [11,12].
Tokola et al. [17] proposed the following budget constraint:
C D ktct C kccc C ktmst C kcnsc : (6)
Here ct > 0 and cc > 0 are the costs for selecting a cluster in the treatment and control conditions,
respectively. Furthermore, st > 0 and sc > 0 are the costs for selecting a patient in the treatment and
control clusters, respectively. It is very likely that the sampling and measuring costs for a cluster are
larger than the costs for sampling and measuring an individual [3,5,17], so it is assumed that ct > st and
cc > sc . Finally, C represents the total research budget.
Minimizing Equation (5) subject to the cost function in Equation (6), employing the method of










Equation (7) shows that the optimal cluster sizes mopt and nopt depend on the ICC for effects, e , and
costs, c , the correlation at individual level, ı", and cluster level, uv , the variance ratio, ', but not on
the total budget C . Also, the optimal cluster sizes mopt and nopt in the treatment and control conditions,
respectively, decrease with increasing subject-specific costs in the treatment, st , and subject-specific
Copyright © 2014 John Wiley & Sons, Ltd. Statist. Med. 2014, 33 2538–2553
2541
M. A. MANJU, M. J. J. M. CANDEL AND M. P. F. BERGER
costs in the control condition, sc , respectively. The optimal cluster sizes in both arms increase as the
cluster-specific costs in the same arm increase.
























Equation (8) shows that the optimal number of clusters ktopt and kcopt depend on the ICC for effects, e ,
and costs, c , the correlation at individual, ı", and cluster level, uv , the variance ratio, ', and total
budget C . The ratio of the optimal number of clusters in the treatment condition, ktopt , versus the number
of clusters in the control condition, kcopt , is the square root of the ratio of cluster-specific costs in the
control condition, cc , versus the cluster-specific costs in the treatment condition, ct .
Substituting the optimal values in Equations (7) and (8) into the variance formula in Equation (5)























Letting '!1 and setting the cluster-specific costs equal for both treatment arms (i.e., ct D cc/ and the
subject-specific costs (i.e., st D sc/, Equation (9) reduces to the optimal variance formula in Moerbeek
et al. [3] for the linear mixed model for effects only.
The optimal design derivation does not provide any solutions for m; n; kt , and kc in case A D 0 or
B D 0. Note that if e D c D 0, then AD 0, and if e D c D 1, then B D 0. So restricting the param-
eters (e; c ; uv; ı", and ') such that A > 0 and B > 0 gives the optimal sample sizes by Equations
(7) and (8).
4. Maximin sample sizes
To compute optimal sample sizes, a priori knowledge about the parameters e; c ; uv; ı", and ' is
needed. Although some systematic reviews suggest plausible ranges for these parameters [18], the
parameters are unknown before data analysis. An incorrect specification of the parameters may lead
to an inefficient design. This is called the local optimality problem [11, 12]: the design is optimal only
for a specific value of the parameter but not within the whole range of values. The approach of this paper
to solve the local optimality problem is the maximin strategy, which guarantees a certain desired level of
power for all parameter values in the range.







of a design [11] and consists of
the following two steps:
(1) Minimize the efficiency .Eff / of estimating the treatment effect estimator across the plausible
ranges for the model parameters .e; c ; uv; ı", and '/. In this step, parameters are chosen to
obtain the worst case in terms of efficiency.
(2) Choose that sample size .m; n; kt ; and kc/, which maximizes this minimum efficiency given a fixed
budget. The sample size that results in the second step optimizes the worst case and is called the
maximin design (MMD).
As the efficiency is the inverse of the asymptotic variance in Equation (5), finding the minimum of
efficiency, amongst others, depends on the range for uv and ı". Based on a review by Gomes et al.
[18], both uv and ı" have negative lower boundaries. Let the realistic ranges for uv and ı" thus be
uv 2 Œr1l ; r1u, where 1 6 r1l < 0 and r1l 6 r1u 6 1, and ı" 2 Œr2l ; r2u, where 1 6 r2l < 0
and r2l 6 r2u 6 1, respectively. As shown in Appendix B, the efficiency is minimum if we start from
the minimum of the two lower boundaries of uv and ı", denoted as r.1 6 r < 0/ D minfr1l ; r2lg.
The spaces for other relevant parameters are the intervals e 2 Œa; b, where 0 < a 6 b < 1; c 2 Œc; d ,
where 0 < c 6 d < 1 and ' 2 Œe; f , where 0 6 e 6 f <1. Note that 0 and 1 were excluded from the
boundaries of e and c , because we could not find a minimum for the efficiency in these cases. It can
be shown that the ICC for effects, e , and costs, c , minimize the efficiency when both are equal to their
2542
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maximum, that is, Dmaxfb; dg. Finally, the efficiency is minimum at the upper bound of the variance
































V.Cij / is the variance of the dependent variable NMBij in Equation (3) under
the maximin values of the parameters.
The maximin sample sizes, which maximize the minimum efficiency in Equation (10), given the


































which implies that the cluster sizes m and n, under the maximin strategy, increase with the cost ratios
ct=st and cc=sc , respectively, and decrease with . On the other hand, the number of clusters increases
with , the total budget C , and decreases with ct=st and cc=:sc .
The maximum variance of the treatment effect estimator for the given ranges of parameter val-






























where … D .e D ; c D ; uv D r; ı" D r; ' D f / is the vector of maximin boundaries. The MMV
increases as specific sampling and measuring costs increase and as  increases, provided  6 0:5 and
ct > st and cc > sc , but decreases as the total budget C increases. Equations (11) and (12) show that the
maximin sample sizes and MMV depend on the choices of boundaries of the intervals for the parameters,
so a different specification of these boundaries of the intervals will give different maximin sample sizes
and corresponding MMV.
5. Robustness of maximin sample sizes
In this study, the maximin sample sizes are derived based on three choices for relevant model parameters.
These choices are the minimum of the two lower boundaries of uv and ı", denoted as r.1 6 r < 0/,
the maximum of the upper bounds of e and c , denoted as , and the upper bound of ', denoted as f .





in Equation (5). The question arises if the
parameter values are not covered by the boundaries as assumed in the maximin strategy. In that case,





may become larger than the MMV. So, we have to check how robust the maximin
sample sizes are against misspecification of boundaries of the parameter intervals. Here, misspecifica-
tion means that the parameter values for e; c , and ' are larger than their assumed upper boundaries







be the variance of the treatment effect estimator in the maximin design
.mMMD; nMMD; ktMMD , and kcMMD/ for parameters outside the maximin boundaries, that is, …1 D
.e; c ; uv; ı"; '/, with e > ; c > ; uv 6 r; ı" 6 r , and ' > f . Robustness is the extent to which
results remain the same if the assumptions that are made to obtain those results are violated [19]. In our
paper, the relative efficiency loss is used to quantify the degree of robustness of a design. The robustness
Copyright © 2014 John Wiley & Sons, Ltd. Statist. Med. 2014, 33 2538–2553
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of the maximin design (MMD) against incorrect specification of the parameters e; c ; uv; ı", and ' is



































fCW.1 /g.f C 1 2r
p
f /
.'e C c  2uv
p




















When …1 D …, that is, uv D ı" D r; e D c D  and ' D f , there is no misspecification,
and the relative efficiency loss (REL) in Equation (13) is equal to zero. If uv < r or ı" < r , the REL
becomes greater than zero. In the same way, the REL will be greater than zero if e > ; c >  or












, and we lose efficiency because of misspecification of parameters in the maximin
design. The value for REL expresses the relative amount of efficiency loss due to misspecification of
parameters in the MMD. Also Equation (13) shows that the REL depends on W , which is a function of
the subject-specific costs and cluster-specific costs and  but is independent of the total budget, C .
Table I displays the parameter boundaries, which are used to investigate the REL numerically. The
MMD and its MMV depend on the lower bounds for uv and ı" and the upper bounds for e; c and
', so we consider only these bounds. In the robustness study, we consider the values of the parameters
that are 1.33 times and twice as large as the values used in the MMD. Furthermore, Table I shows two
different sets of maximin boundaries: one is from a review (based on 62 empirical studies) by Gomes
et al. [18] except for ', which is based on the six other studies [4, 10, 20–23], and another one in which
the parameter spaces are assumed to be smaller. In some studies, researchers may find the Gomes et al.
[18] intervals too broad. For instance, some other systematic reviews indicate that the ICC for effects
rarely exceeds 0.025 in medical and health science studies [24]. As another illustration, a smaller value
of the ICC for effects .e D 0:04/ is reported by Morrell et al. [2] in a healthcare intervention study to be
discussed in Section 7. This motivates considering a second set of smaller intervals and corresponding
boundaries. So Table I contains large and small maximin boundaries and the corresponding boundary
values as used in the robustness study to examine the effect of misspecification. As an example, the ICC
for effects e has upper boundaries 0.3 and 0.1, respectively, which are used in the maximin strategy
for two different MMDs. Then, in the robustness study, we consider e D 0:4 and e D 0:13 as 25%
misspecifications of these boundaries, respectively, to study how much efficiency the MMD loses.
Table I. Boundary values used in the numerical robustness study of the maximin design (MMD).
Boundary values in the robustness study
Large boundary Small boundary
Assumed boundary values in the MMD
25% 50% 25% 50%
Parameters Large boundary Small boundary misspecification misspecification misspecification misspecification
e (UB) 0.3 0.1 0.4 0.6 0.13 0.2
c (UB) 0.3 0.1 0.4 0.6 0.13 0.2
' (UB) 50 20 66.67 100 26.67 40
uv (LB) 0.5 0.3 0.67 1.0 0.4 0.6
ı" (LB) 0.5 0.3 0.67 1.0 0.4 0.6
Note: The large maximin boundary values are based on a review by Gomes et al. [18] except for ', which is based on
the six other studies.
UB, upper bound; LB, lower bound.
2544
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be the relative efficiency losses in the MMD when the ICC for effects, e ,
is not misspecified (that is, e D / and is misspecified by 25% (that is, e D .10:25/1/, respectively.
In both cases, the other parameters‚D .c ; uv; ı"; '/, with c > ; uv 6 r; ı" 6 r , and ' > f , may




























Equation (14) represents the amount of REL that is only due to misspecification of the ICC for effects,
e , by 25%. This contribution to REL can be examined with other parameters ‚ D .c ; uv; ı"; '/
possibly also being misspecified. Further, let N25%e be the efficiency loss of misspecifying the ICC for
effects e by 25%, averaged across all possible choices of the other parameters ‚ D .c ; uv; ı"; '/
that are misspecified maximally by 50%. The notation25%e can be generalized to all the parameters by
the term p and the corresponding average by Np , where p is either 25% or 50%, and  stands for
any one of e; c ; uv; ı", and '.




, and maximum efficiency loss for the misspecifications
of each parameter in the case the maximin design is based on the large maximin boundaries in Table I.
These results are shown for different values of W between 0 and 0.65. Notice that W in Equation (13)
Table II. Minimum (Min), average (Ave), and maximum (Max) efficiency losses for 25% and 50% mis-
specifications of each parameter for different values of W , when the other parameters are misspecified 50%
at most.
Correlation between Correlation between
costs and effects at costs and effects at
Contribution
ICC for effects ICC for costs cluster level individual level Variance ratio
to REL
.e/ .c/ .uv/ .ı"/ .'/
W .p / 25% 50% 25% 50% 25% 50% 25% 50% 25% 50%
0.00 Min 0.1001 0.2058 0.0031 0.0083 0.0059 0.0166 0.0000 0.0000 0.1001 0.2058
Ave 0.1615 0.3307 0.0132 0.0345 0.0211 0.0579 0.0000 0.0000 0.1616 0.3307
Max 0.2342 0.4768 0.0332 0.0849 0.0486 0.1301 0.0000 0.0000 0.2342 0.4768
0.10 Min 0.0811 0.1779 0.0029 0.0076 0.0062 0.0177 0.0004 0.0014 0.1157 0.2379
Ave 0.1277 0.2800 0.0108 0.0279 0.0191 0.0528 0.0026 0.0078 0.1721 0.3521
Max 0.1823 0.3989 0.0265 0.0680 0.0413 0.1122 0.0077 0.0225 0.2342 0.4768
0.20 Min 0.0656 0.1517 0.0026 0.0066 0.0064 0.0183 0.0010 0.0030 0.1295 0.2663
Ave 0.1013 0.2347 0.0089 0.0226 0.0175 0.0489 0.0048 0.0141 0.1808 0.3698
Max 0.1427 0.3309 0.0216 0.0550 0.0359 0.0985 0.0130 0.0373 0.2342 0.4768
0.30 Min 0.0526 0.1273 0.0019 0.0036 0.0065 0.0186 0.0016 0.0047 0.1418 0.2915
Ave 0.0800 0.1941 0.0073 0.0182 0.0163 0.0456 0.0067 0.0194 0.1881 0.3847
Max 0.1115 0.2711 0.0177 0.0449 0.0317 0.0878 0.0167 0.0477 0.2342 0.4768
0.40 Min 0.0407 0.1028 0.0008 0.0004 0.0066 0.0188 0.0022 0.0064 0.1527 0.3141
Ave 0.0626 0.1576 0.0060 0.0145 0.0152 0.0429 0.0083 0.0240 0.1944 0.3975
Max 0.0876 0.2200 0.0147 0.0367 0.0284 0.0791 0.0195 0.0555 0.2342 0.4768
0.50 Min 0.0306 0.0801 0.0000 0.0042 0.0065 0.0188 0.0028 0.0082 0.1626 0.3344
Ave 0.0481 0.1247 0.0049 0.0112 0.0144 0.0406 0.0098 0.0280 0.1998 0.4086
Max 0.0681 0.1764 0.0132 0.0334 0.0257 0.0720 0.0218 0.0615 0.2342 0.4768
0.60 Min 0.0217 0.0583 0.0015 0.0095 0.0059 0.0171 0.0034 0.0099 0.1715 0.3527
Ave 0.0358 0.0949 0.0039 0.0083 0.0136 0.0386 0.0110 0.0315 0.2046 0.4183
Max 0.0535 0.1388 0.0127 0.0318 0.0246 0.0685 0.0235 0.0663 0.2342 0.4768
0.65 Min 0.0178 0.0482 0.0022 0.0117 0.0056 0.0163 0.0037 0.0108 0.1757 0.3613
Ave 0.0303 0.0810 0.0035 0.0070 0.0133 0.0376 0.0116 0.0331 0.2068 0.4227
Max 0.0469 0.1228 0.0124 0.0309 0.0246 0.0687 0.0243 0.0683 0.2342 0.4768
Note: In the maximin design, the ICC for effects and costs is set to D 0:3, the cluster and individual level correlations
are set to r D 0:5 based on Gomes et al. [18], and the variance ratio is set to f D 50 (from six other studies). W is a
function of cluster-specific and subject-specific costs and  as defined in Equation (13).
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cannot be larger than 0.65, as ct > st ; cc > sc , and D 0:3. Table II shows that, when the ICC for effects,
e , is misspecified by 25% and 50%, the maximum contribution to the efficiency loss can become 23.4%
and 47.7%, respectively, occurring at W D 0. The case W D 0 means that the cost at cluster level is
infinitely large compared with the subject-specific cost, therefore being a rather exceptional case. The
contribution to the efficiency loss due to misspecification of e decreases withW . Similarly, the ICC for
costs, c , contributes maximally to REL at W D 0: its contribution is 3.3% and 8.5%, for 25% and 50%
misspecifications of c , respectively.
Table II shows that the contribution to the efficiency loss is much larger for e than for c . The
efficiency loss of misspecifying e and c depends on the upper bound of '. It can be shown that mis-
specification of e and c contributes equally to REL if ' D 1. If ' > 1, then e contributes to REL
more than c , but if ' < 1, then c contributes more than e . The explanation is that if ' > 1, then
the variance of effects translated into a monetary scale .Eij / is larger than the total variance for costs











than misspecifying c .
For W > 0:50, the minimum efficiency loss due to misspecification of c can become negative
(Table II), which means that we obtain some efficiency gain due to misspecification. This occurs in
a few cases when other parameters are also misspecified. It should be noted that W > 0:50 results in
maximin cluster sizes less than or equal to two in at least one of the treatment conditions. This follows
from the definition of W (in terms of costs) and the results in Equation (11). So the efficiency gain
Table III. Minimum (Min), average (Ave), and maximum (Max) efficiency losses for 25% and 50% mis-
specifications of each parameter for different values of W , when the other parameters are misspecified 50%
at most.
Correlation between Correlation between
costs and effects at costs and effects at
Contribution
ICC for effects ICC for costs cluster level individual level Variance ratio
to REL
.e/ .c/ .uv/ .ı"/ .'/
W .p / 25% 50% 25% 50% 25% 50% 25% 50% 25% 50%
0.00 Min 0.0915 0.2054 0.0033 0.0098 0.0055 0.0160 0.0000 0.0000 0.0994 0.2054
Ave 0.1466 0.3275 0.0142 0.0415 0.0195 0.0548 0.0000 0.0000 0.1603 0.3299
Max 0.2120 0.4713 0.0344 0.0978 0.0429 0.1177 0.0000 0.0000 0.2303 0.4713
0.05 Min 0.0680 0.1674 0.0029 0.0088 0.0053 0.0156 0.0013 0.0038 0.1202 0.2482
Ave 0.1057 0.2603 0.0106 0.0314 0.0154 0.0440 0.0049 0.0144 0.1739 0.3575
Max 0.1499 0.3685 0.0248 0.0717 0.0318 0.0893 0.0115 0.0339 0.2303 0.4713
0.10 Min 0.0528 0.1381 0.0025 0.0076 0.0050 0.0146 0.0025 0.0075 0.1350 0.2788
Ave 0.0807 0.2117 0.0084 0.0249 0.0128 0.0370 0.0081 0.0238 0.1828 0.3757
Max 0.1131 0.296 0.0190 0.0556 0.0252 0.0719 0.0175 0.0509 0.2303 0.4713
0.15 Min 0.0423 0.1153 0.0022 0.0065 0.0046 0.0136 0.0036 0.0108 0.1461 0.3017
Ave 0.0639 0.1751 0.0068 0.0203 0.0110 0.0321 0.0105 0.0306 0.1891 0.3886
Max 0.0886 0.2434 0.0152 0.0446 0.0209 0.0601 0.0212 0.0611 0.2303 0.4713
0.20 Min 0.0345 0.0972 0.0018 0.0054 0.0043 0.0126 0.0046 0.0136 0.1547 0.3195
Ave 0.0517 0.1465 0.0057 0.0168 0.0097 0.0284 0.0123 0.0357 0.1938 0.3983
Max 0.0713 0.2025 0.0125 0.0368 0.0178 0.0516 0.0237 0.0678 0.2303 0.4713
0.25 Min 0.0282 0.0824 0.0015 0.0043 0.0039 0.0117 0.0055 0.0160 0.1616 0.3338
Ave 0.0426 0.1236 0.0048 0.0141 0.0087 0.0254 0.0138 0.0398 0.1975 0.4058
Max 0.0586 0.1700 0.0105 0.0308 0.0156 0.0454 0.0254 0.0727 0.2303 0.4713
0.30 Min 0.0231 0.0691 0.0011 0.0030 0.0035 0.0105 0.0062 0.0182 0.1673 0.3455
Ave 0.0354 0.1049 0.0041 0.0119 0.0078 0.0230 0.0149 0.0431 0.2004 0.4119
Max 0.0496 0.1445 0.0090 0.0265 0.0141 0.0413 0.0268 0.0763 0.2303 0.4713
0.33 Min 0.0206 0.0622 0.0009 0.0024 0.0033 0.0097 0.0066 0.0193 0.1702 0.3515
Ave 0.0319 0.0951 0.0037 0.0108 0.0074 0.0218 0.0156 0.0447 0.2019 0.4149
Max 0.0451 0.1326 0.0084 0.0246 0.0137 0.0398 0.0274 0.0781 0.2303 0.4713
Note: In the maximin design, the ICC for effects and costs are set to D 0:1, the cluster and individual level correlations
are set to r D0:3, and the variance ratio is set to f D 20.W is a function of cluster-specific and subject-specific costs
and  as defined in Equation (13).
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only occurs when at least one of the treatment conditions has clusters with one or two individuals in
each cluster. In practice, because of logistic reasons, CRTs often will have a larger number of persons in
each cluster.
For the correlation at cluster level, uv , the maximum efficiency losses occur at W D 0, which are
4.9% and 13%, respectively. Misspecifying ı" leads to an even smaller efficiency loss when compared
with the efficiency loss for misspecifying uv . The increases of REL due to misspecification of ı"
become maximum at W D 0:65, which are 2.4% and 6.8%. The value 0.65 for W is its maximum for
 D 0:3 and occurs when spending the same costs for selecting a cluster and a subject in each of the
treatment arms. The effect of misspecification of the variance ratio ' is largest compared with the effect
of misspecifying the other parameters. The largest contribution to REL due to misspecification of ' is
about 47.7%.
In Table III, we examined the robustness of the MMD when the smaller boundaries of the parameters
in Table I are taken as the maximin boundaries. The maximum value ofW for D 0:1 becomes 0.33. The
results in Table III make clear that the efficiency losses of the MMD due to misspecification of parame-
ters are similar to those in Table II. In addition, all possible combinations of small and large parameter
boundaries additionally yield six different sets of maximin boundaries, which were also investigated.
The results were analogous to those shown in Tables II and III and for that reason were omitted.
The numerical evaluations in Tables II and III show that the MMD is rather robust against misspec-
ification of the parameters uv; ı", and c , whereas misspecifying the parameters e and ' result in
relatively large efficiency losses. The robustness of the MMD against misspecification of the model
parameters can be summarized as follows:
(a) The contribution to REL due to misspecification of uv or ı" never exceeds 13%, and misspecifi-
cation of the individual level correlation ı" leads to less efficiency loss than uv . So the MMD is
rather robust against misspecification of the correlations at the cluster and individual levels.
(b) We assumed an upper boundary for ' based on six available studies. For this upper bound and
a smaller one (Table I), the MMD turned out to be rather sensitive to misspecification of this
parameter.
(c) For the upper boundaries of ' considered in this study, the MMD is robust under misspecification
of the ICC for costs c , whereas the MMD is sensitive to the misspecification of the ICC for effects
e . The maximum contribution to REL is about 47.7%.
6. Power of the test on cost-effectiveness of a treatment
The average INMB .ˇ1/ represents the cost-effectiveness of an intervention. Suppose we want to test the
null hypothesis H0 W ˇ1 D 0 against the alternative hypothesis HA W ˇ1 > 0, that is, the intervention is
cost-effective. To test these hypotheses, use can be made of the ML estimator Ǒ1 (Equation (4)), which













mated by a standard normal distribution if the number of clusters is large enough [25]. For a one-sided
test with alternative hypothesis HA W ˇ1 > 0, with power .1 / at ˇ1 and with a type I error rate ˛, we
have [25, p. 142]








where ´1˛ and ´1 are the .1 ˛/ and .1 / percentiles of the standard normal cumulative distri-
bution function. For a two-sided alternative HA W ˇ1 ¤ 0, the percentile value ´1˛ in Equation (15) is
replaced by ´1 =̨2. Cohen [26] introduced the effect size ES D jˇ1j =
p
V.NMBij /, where V.NMBij /
is the variance of NMBij in Equation (3) and also proposed a classification into small (0.2), medium
(0.5), and large (0.8) effect sizes. Equation (15) can be expressed in terms of the effect size (ES) in the
following way:

















where A and B are defined as in Equation (5).
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7. Application in planning a cost-effectiveness CRT
The optimal design as well as the MMD for the nested NMB model will be applied to a case study known
as the PONDER study [2]. This study involves the assessment of two alternative interventions com-
pared with usual care for preventing postnatal depression. The clusters (here: general practices) were
randomly allocated to either a control group (usual care) or a treatment group (one of the two interven-
tions termed as the Person Centered Approach and the Cognitive-Behavioral Approach). To establish
the cost-effectiveness of the treatment group compared with the control group, data were obtained from
87 general practices (kt D 58 treatment clusters and kc D 29 control clusters) with, on the average,
mD nD 6women in each general practice. The effects and costs were expressed in terms of QALYs and
UK pounds (£), respectively. A high ICC was found for costs, c D 0:17, but not for effects e D 0:04.
There was a negative individual level correlation .ı" D 0:06/ between costs and effects, whereas the
correlation between costs and effects at the cluster level was positive .uv D 0:04/. For a ceiling ratio of
D 20; 000, the variance ratio ' turned out to be 4.32.
The design of the PONDER study is kt D 58; kc D 29;mD nD 6, which we call the actual design. In
the sequel, the optimal design of the PONDER study is examined, based on the parameter estimates as
found in the PONDER study by Morrell et al. [2],…PONDER D .e D 0:04; c D 0:17; uv D 0:04; ı" D
0:06; ' D 4:32/. If we know the actual parameter values, we can calculate the optimal design. As this
may not be the case in practice, a solution is to formulate a MMD based on the large maximin bound-
aries in Table I, …LARGE D .e D 0:3; c D 0:3; uv D0:5; ı" D0:5; ' D 50/. Table IV shows four
relative efficiencies of the aforementioned three designs. As the exact cost ratios for this study were not
Table IV. Relative efficiencies of the actual design of the PONDER study [2] (ACT), the maximin design
(MMD), and the optimal design (opt), for the parameters in the PONDER study,…PONDER, and the parameters
in …LARGE, specified for different cost ratios.
Cost Cost Subject
ratio for ratio for specific
treatment control cost
condition condition ratio






































2 2 1 0.89 0.84 0.69 0.80
2 10 1 0.90 0.81 0.87 0.81
2 50 1 0.69 0.80 0.89 0.84
10 2 1 0.72 0.81 0.70 0.81
10 10 1 0.78 0.80 0.88 0.82
10 50 1 0.69 0.80 0.96 0.85
50 2 1 0.41 0.80 0.53 0.84
50 10 1 0.47 0.80 0.66 0.85
50 50 1 0.53 0.81 0.84 0.87
2 2 4 0.67 0.84 0.52 0.80
2 10 4 0.74 0.82 0.67 0.81
2 50 4 0.73 0.80 0.81 0.82
10 2 4 0.52 0.81 0.54 0.81
10 10 4 0.58 0.80 0.66 0.82
10 50 4 0.64 0.80 0.84 0.84
50 2 4 0.30 0.80 0.43 0.85
50 10 4 0.34 0.81 0.50 0.86
50 50 4 0.40 0.81 0.63 0.87
2 2 9 0.56 0.84 0.44 0.80
2 10 9 0.62 0.82 0.55 0.80
2 50 9 0.68 0.81 0.73 0.82
10 2 9 0.45 0.81 0.47 0.81
10 10 9 0.49 0.80 0.56 0.82
10 50 9 0.56 0.80 0.72 0.84
50 2 9 0.27 0.81 0.39 0.86
50 10 9 0.29 0.81 0.44 0.86
50 50 9 0.34 0.81 0.53 0.87
Note: Maximin design (MMD) is always based on the parameter vector…LARGE in Table I, and the optimal design (opt)
is based on the parameter estimates as found in the PONDER study, …PONDER.
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known, we evaluated the efficiencies for several cost ratios, comprising the cost ratios of other studies.
Raudenbush [5] used 2, 10, and 50 as the values for cluster to subject-specific cost ratios .ct=st ; cc=sc/,
and, similar to Liu [27], the subject-specific cost ratios of treatment to control arm .st=sc/ were equal
to 4 and 9. For the first two relative efficiencies in Table IV, it is assumed that …PONDER is the set of
parameter values; therefore, the MMD and actual design become suboptimal compared with the optimal
design of the PONDER study. The first relative efficiency shows that the optimal design can become
much more efficient than the actual design (up to three times as efficient) especially for large cost ratios.
The second relative efficiency shows that the MMD loses at most 20% efficiency compared with the
optimal design. The last two columns of Table IV assume …LARGE is the set of parameter values. In
that case, the MMD becomes optimal compared with the other two designs. The efficiency of the actual
design to the MMD is shown in the third relative efficiency column. As can be seen, the MMD can also
be much more efficient than the actual design of the PONDER study. The last column shows that the
design, which is optimal for …PONDER, is at most 20% less efficient than the MMD if the large maximin
boundaries in Table I, …LARGE, are assumed to be the parameter values.
Next we consider how the optimal design, the MMD, and the actual design of the PONDER study
relate to power for varying effect size .ES/. Figure 1 displays the power against effect size for the opti-
mal design (Equations (7) and (8)), the MMD (Equation (11)), and the actual design of the PONDER
study for ˛ D 0:05 in a one-sided test. We compared these three designs, assuming …PONDER is the
parameter vector, for four different sets of cost ratios. Notice that the MMD is based on the large ICC
value  D 0:3 for both costs and effects, which results in smaller power for the MMD than the optimal
design. The power of the optimal design and the MMD are larger than the actual design of the PONDER
study. This is in line with the results of Table IV. The difference in power between the optimal design and
actual design of the PONDER study increases as the cost ratios increase and the maximum difference
Optimal design Maximin design Actual design of the PONDER study
Figure 1. Statistical power for the optimal design, the MMD, and the actual design of the PONDER study for the
parameter vector …PONDER D .e D 0:04; c D 0:17; uv D 0:04; ı" D 0:06; ' D 4:32/ as a function of the
effect size, ESD jˇ1j =
p
V.NMBij /, under four different sets of cost ratios.
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ranges between 0.08 and 0.33 for the effect sizes around 0.20. On the contrary, the power difference
between the optimal design and the MMD remains approximately the same, even for larger cost ratios.
8. Discussion and conclusions
This paper makes two important contributions to sample size calculation in cost-effectiveness CRTs.
First, our study takes into account the hierarchical characteristic of cost-effectiveness data, which were
ignored by approaches available in the literature on sample size calculation for cost-effectiveness studies.
Second, we propose formulas for sample size calculation that maximize the efficiency of the treatment
effect estimator given a budget constraint. The hierarchical net-benefit regression was taken as a frame-
work for the CEA of interventions. More specifically, we started from the model in Equation (3) that
relates treatment condition to a quantitative outcome known as net monetary benefit. The model further-
more assumes that there are random cluster effects, thus taking into account the dependency between
subjects within the same cluster. In this model, commonly the average INMB is of main interest, and
an optimal design was derived to estimate the average INMB as efficiently as possible given a fixed
research budget.
The optimal sample sizes require information on the ICCs for effects and costs, the correlations
between costs and effects at the individual and cluster levels, the ratio of the variance of effects translated
into costs to the variance of the costs (the variance ratio), sampling and measuring costs, and the budget.
When planning a study, information on the model parameters usually is not available, and a maximin
design (MMD) is proposed to handle this local optimality problem. A robustness study was carried out
on the effects of misspecifying parameters in the maximin design. Although the numerical evaluation
shows the MMD to be robust against misspecification of the ICC for costs and the correlation between
costs and effects at the cluster and individual levels, the MMD may lose much efficiency because of mis-
specification of the ICC for effects and the variance ratio. Note that the upper boundaries for the variance
ratio used in the numerical evaluation are greater than one, which implies more efficiency loss when the
ICC for effects is misspecified. On the other hand, if the upper bound for the variance ratio is less than
one, the MMD will become more sensitive against the misspecification of the ICC for costs. Further, as
the ceiling ratio  determines whether the variance ratio is greater than, or less than, or equal to one,
 also determines whether the MMD is more sensitive against misspecification of the ICC for effects
or costs. The empirical evidence on the variance ratio is rather scarce, and its misspecification in the
MMD showed large efficiency losses, so future studies should provide specific results on this parameter.
Finally, a practical expression is given in Equation (16), which shows the relation between the sam-
ple sizes (either optimal or maximin), effect size, and the power of a test on the cost-effectiveness of
two interventions.
The current study has some limitations. First, the distribution of costs as part of the outcome variable
is assumed to be normal, but in practice, cost data may be positively skewed. However, some studies sup-
port the robustness against violating the normality assumption in hierarchical modeling [28, 29]. Note
that the estimator Ǒ1 in Equation (4) is the difference between the averages of outcomes in the treatment
arms. By the central limit theorem, these averages will be approximately normally distributed, even for
skewed cost data, if there is a large number of clusters. Second, we assumed only equal numbers of indi-
viduals in each cluster in the treatment and control conditions, but in practice, because of non-response
and dropout, cluster sizes may become unequal. One solution could be to use the correction methods
as proposed by Van Breukelen et al. [30] and Candel et al. [31] to adjust the sample sizes as computed
under the assumption of equal cluster sizes. Third, this study did not include any covariates in the models
in Equations (1) and (3). However, for CRTs, the sample size formulas for a model without covariates
also hold for a model with covariates [32]. Of course, adding covariates at either the cluster level or the
individual level may decrease the variance components, which results in more precise estimates of the
treatment’s cost-effectiveness and increases statistical power. Hence if we would include covariates in
the analysis, but would ignore this in the sample size calculation, our formulas would lead to the sample
sizes that are too large, therefore being on the safe side in terms of efficiency. Obtaining cost-efficient
sample sizes would of course require estimates of the variance components corrected for covariates.
Fourth, the cluster level variance and the cluster level correlation, together with the individual level vari-
ance and individual level correlation, are assumed to be equal between the treatment arms. As some
reviews [4, 33] suggest that the treatments may have unequal variances and correlations, an interesting
issue for future research would be how the optimal and maximin design approach could account for this
between-arm heterogeneity of model parameters.
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Appendix A. Derivation of the optimal number of clusters and cluster sizes






in terms of the model parameters e; c ; uv; ı", and '. Second, we have to
define a budget constraint and then obtain the number of clusters and cluster sizes, which minimize the
variance of Ǒ1 subject to the specified budget constraint.
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in Equation (A.2), under a
budget constraint C D ktct C kccc C ktmst C kcnsc , where ct > 0; cc > 0; st > 0, and sc > 0,






Cƒ.ktct C kccc C ktmst C kcnsc C/; (A.3)
where ƒ is the Lagrange multiplier. Setting the partial derivatives of Equation (A.3) with respect to
m; n; kt ; kc , and ƒ equal to zero gives the optimal number of clusters and sample size per cluster in
each of the treatment arms, as displayed in Equations (7) and (8) of the main text. Finally, inserting
Equations (7) and (8) into Equation (A.2) yields the optimal variance as shown in Equation (9) of the
main text.
Appendix B: Derivation of the maximin sample sizes and its MMV
First, we have to find out which values of the parameters in the assumed ranges minimize the efficiency







































, and .P  Q/ > 0 for all m; n; kt , and kc . The partial
derivatives of Equation (B.1) with respect to uv and ı" become
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p
.1 e/.1 c/' > 0, respectively. These partial derivatives show that
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the efficiency always goes up as uv and ı" increase. So the minimum efficiency occurs at the lower
boundaries of uv and ı". A systematic review of 62 empirical studies by Gomes et al. [18] shows that
both uv and ı" have negative lower boundaries, say r1l.16 r1l < 0/ and r2l.16 r2l < 0/ (l stands
for lower boundary), respectively. It is to be noted that the minimum efficiency with respect e and c
also depends on the value of uv and ı". The Gomes et al. [18] review suggests r1l D r2l , but it may
be that r1l ¤ r2l . However, it turns out that in order to find values for e and c , which minimize the
efficiency, it is necessary to assume that uv D ı" D min fr1l ; r2lg D r.1 6 r < 0/. This minimizes
the efficiency more than needed if r1l ¤ r2l but at least guarantees a certain power level also in this case.
The minimum efficiency is then given by
Eff  D
h
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> 0, which is
equivalent to .c  ec/ > .e  ec/ and then @Eff

@e




if .e  ec/ > .c  ec/ or e > c . So the efficiency will be minimum for both e and c if
e D c D  D maxfb; dg, where e 2 Œa; b with 0 < a 6 b < 1 and c 2 Œc; d  with 0 < c 6 d < 1
are the realistic ranges for the parameters e and c , respectively. The minimum efficiency with respect
to model parameters is thus obtained by substituting uv D ı" D r; e D c D  and ' D f into
Equation (B.1). This yields Equation (10) in the main text. Maximizing Equation (10) under the budget
constraint in (6) yields the maximin sample sizes in Equation (11). The corresponding MMV is obtained
by inserting Equation (11) into (10), giving Equation (12) of the main text.
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